港股異動 | 康哲藥業漲超6%,獲花旗唱好
uSMART盈立智投3月18日消息,週四港股早盤,康哲藥業高開高走,截至9:42分,康哲藥業漲超6%。報16.88港元,創逾2年高位。
花旗稱,考慮到康哲藥業的醫美和大健康業務可能成爲新的增長引擎,上調公司評級至買入,並將目標價從11.1港元大幅調升至26港元。
分析師Cui Cui等在報告中指出,管理層承諾每年獲得5種有競爭力的創新藥許可,同時公司還有幾種藥品預計將在未來幾年在中國推出。
分別上調公司2021和2022年的盈利預測39%和57%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.